1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Syndax's Newly Arrived CEO Briggs Morrison Announces Clinical Collaboration With Genentech

 
• By Sten Stovall

Syndax Pharmaceuticals Inc. - which recently lured respected scientist Briggs Morrison away from AstraZeneca to be its CEO - has entered a clinical collaboration with Genentech Inc. to evaluate the safety, tolerability and preliminary efficacy of its lead asset, entinostat, an oral small molecule targeting immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with the Roche Holding AG biologics division's PD-L1 inhibitor atezolizumab in patients with triple-negative breast cancer.

Syndax Pharmaceuticals Inc. - which recently lured respected scientist Briggs Morrison away from AstraZeneca to be its CEO - has entered a clinical collaboration with Genentech Inc. to evaluate the safety, tolerability and preliminary efficacy of its lead asset, entinostat, an oral small molecule targeting immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with the Roche Holding AG biologics division's PD-L1 inhibitor atezolizumab in patients with triple-negative breast cancer.

Under terms of the deal, announced on Aug. 27, Syndax will conduct the Phase Ib/II trial in triple-negative breast cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

More from Therapy Areas

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.